Lung cancer screening program using a blood test and pharmacist referrals
Official title: CHAMP: Community Health Assessment and Monitoring in the Pharmacy. Assessing the Impact of a Community Pharmacist Lung Cancer Screening (LCS) Program
Run by University of Iowa · NCT07572773 · Data updated 2026-11-12
This program tests a blood test plus a pharmacist-led referral to see if screening for lung cancer can be made easier for eligible adults in Iowa.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years to 77 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University of Iowa Academic / other |
| Locations | 3 sites (Iowa City, Iowa and 2 other locations) |
| Status | Recruiting |
| Started | June 12, 2026 |
| Main results expected | June 2028 |
| Study ends | June 2028 |
| Registry record updated | June 16, 2026 |
| Trial ID | NCT07572773 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 50-77 with a ≥20 pack-year smoking history who are current smokers or quit within the last 15 years and can provide informed consent.
✕Probably not a fit
Individuals who do not pursue screening options or who have contraindications to either the blood test or CT screening may receive standard care without additional benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study examines whether a blood-based screening test (DELFI FirstLook) combined with a community pharmacist referral program increases lung cancer screening uptake among adults aged 50-77 with a significant smoking history in Iowa. Eligible participants identify at Greenwood Pharmacy in Waterloo, discuss options with a pharmacist, and choose among declination, DELFI blood test, or CT screening through their clinician. The approach aims to reduce screening complexity and integrate referral into routine pharmacy care. Primary support comes from a collaboration between the University of Iowa, Cedar Valley Primary Care, Greenwood Pharmacy, and partner Eli Lilly, with lead sponsor Jill Kolesar.
Why it matters
Potential benefit: If successful, participants may receive a simpler pathway to early lung cancer detection and potentially improved health outcomes through earlier intervention.
How similar studies have gone: Prior efforts show that pharmacy-based outreach and simplified screening processes can improve participation, though results vary by setting and screening modality.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged 50-77 * smoking pack-year history of ≥ 20 years * current smoker or quit smoking 15 or less years ago * ability to understand and willingness to sign a written informed consent document Exclusion Criteria: * self-report of lung cancer screening in the last 12 months * psychiatric illness/social situations that would limit compliance with study requirements
Where it's running
-
University of Iowa
Iowa City, Iowa, United States Recruiting -
Cedar Valley Primary Care & Walk-In Clinic
Waterloo, Iowa, United States Recruiting -
Greenwood Pharmacy and Compounding Center
Waterloo, Iowa, United States Recruiting
Study contacts
- Principal investigator: Jill Kolesar, PharmD, MS, FCCP — University of Iowa
- Study coordinator: Laura Seegmiller
- Email: champ-study@uiowa.edu
- Phone: (319) 384-1494
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Liquid biopsy pre-screen to reduce unnecessary low-dose CT for high-risk lung cancer
This will test a blood-based liquid biopsy to see if it can identify high-risk people who can safely skip or delay a low-dose CT scan for lung cancer.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.